Brief: Ionis Pharmaceuticals Inc - Zilganersen 50 Mg Meets Primary Endpoint, Stabilizes Gait Speed In Patients ≥5 Years At Week 61
21/04/2026 13:02
April 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS PHARMACEUTICALS INC - ZILGANERSEN 50 MG MEETS PRIMARY ENDPOINT, STABILIZES GAIT SPEED IN PATIENTS ≥5 YEARS AT WEEK 61 IONIS PHARMACEUTICALS INC - KEY SECONDARY ENDPOINT RESULTS CONSISTENTLY FAVORED ZILGANERSEN OVER CONTROL IONIS PHARMACEUTICALS INC - ZILGANERSEN UNDER FDA PRIORITY REVIEW WITH PDUFA DATE SET FOR SEPTEMBER 22, 2026 Source text: ID:nBw64D5kma Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors